On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.’s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease.
Pharmalittle: We’re reading about a Purdue overdose-reversal device, a discontinued Merck trial, and more
Top of the morning to you, and a fine one it is, despite the gray skies hovering over the Pharmalot campus. We are doing our
August 8, 2024